重组胶原蛋白产品质量争议
Search documents
港股异动 | 巨子生物(02367)盘中重挫15% 可复美成分之争再起波澜 华熙生物称已提交数...
Xin Lang Cai Jing· 2025-09-24 08:01
Core Viewpoint - The stock of Giant Bio (02367) experienced a significant decline of 15% during trading, with a current drop of 11.8%, trading at HKD 54.2, and a transaction volume of HKD 1.716 billion. This decline is linked to allegations regarding the quality of its collagen products, which have raised concerns about potential false advertising [1]. Group 1: Company Response and Actions - Huaxi Biological has officially responded to the situation involving Dr. Hao Yu, stating that after receiving his request for assistance, it collaborated with multiple third-party testing organizations to assess the relevant products, revealing that the recombinant collagen content did not meet standards in several test results [1]. - Huaxi Biological has submitted dozens of test reports to the National Medical Products Administration, indicating a proactive approach to addressing the allegations [1]. Group 2: Allegations and Product Quality Issues - On May 24, beauty blogger Dr. Hao Yu published a report claiming that the collagen content in Giant Bio's "Collagen Stick" was only 0.0177%, significantly below the advertised standard, and that a key amino acid, glycine, was "not detected," raising suspicions of false advertising [1]. - Giant Bio quickly denied these claims, asserting that their products comply with regulations and that internal testing results exceed 0.1% [1]. - Following a series of exchanges, on June 23, Giant Bio acknowledged that its existing quality standards, testing methods, and labeling have shown limitations in certain aspects [1].
港股异动 | 巨子生物(02367)盘中重挫15% 可复美成分之争再起波澜 华熙生物称已提交数十份检测报告
智通财经网· 2025-09-24 07:52
Core Viewpoint - The stock of Giant Bio (02367) experienced a significant decline of 15% during trading, with a current drop of 11.8%, trading at HKD 54.2, and a transaction volume of HKD 1.716 billion [1] Group 1: Company Response and Actions - Huaxi Bio has officially responded to the controversy surrounding Dr. Hao Yu, stating that it has collaborated with multiple third-party testing organizations to assess related products, revealing that the recombinant collagen protein content did not meet standards in several test results [1] - Huaxi Bio has submitted dozens of test reports to the National Medical Products Administration [1] - Giant Bio quickly denied the allegations, asserting that its product complies with standards and that internal testing results exceed 0.1% [1] Group 2: Controversy and Public Reactions - On May 24, beauty blogger Dr. Hao Yu released a test report claiming that the actual recombinant collagen protein content in Giant Bio's "Collagen Stick" was only 0.0177%, significantly lower than advertised, and that the key amino acid glycine was "not detected," raising concerns of false advertising [1] - Following the initial claims, Giant Bio received an apology from the testing organization used by Dr. Hao Yu, stating that it had "never authorized Dr. Hao to use the report" [1] - On June 23, Giant Bio acknowledged that its "existing quality standards, testing methods, and labeling have gradually shown limitations in certain aspects" [1]
巨子生物盘中重挫15% 可复美成分之争再起波澜 华熙生物称已提交数十份检测报告
Zhi Tong Cai Jing· 2025-09-24 07:51
Core Viewpoint - The stock of Giant Bio (02367) experienced a significant decline of 15% during trading, with a current drop of 11.8%, trading at HKD 54.2, and a transaction volume of HKD 1.716 billion. This decline is linked to allegations regarding the quality of its collagen products, which have raised concerns about potential false advertising [1]. Group 1: Company Response and Actions - Huaxi Biological has officially responded to the situation involving Dr. Hao Yu, stating that after receiving his request for assistance, it collaborated with multiple third-party testing organizations to conduct tests on related products, revealing that the recombinant collagen content did not meet standards [1]. - Huaxi Biological has submitted dozens of test reports to the National Medical Products Administration, indicating a proactive approach to address the allegations [1]. Group 2: Allegations and Product Quality Issues - On May 24, beauty blogger Dr. Hao Yu released a report claiming that the actual recombinant collagen content in Giant Bio's "Collagen Stick" was only 0.0177%, significantly lower than advertised, and that a key amino acid, glycine, was "not detected," raising suspicions of false advertising [1]. - Giant Bio quickly denied these claims, asserting that its products comply with regulations and that internal testing showed results exceeding 0.1% [1]. - On June 23, Giant Bio acknowledged that its existing quality standards, testing methods, and labeling have shown limitations in certain aspects, indicating a recognition of potential issues within its product quality assurance processes [1].